Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut.
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida.
J Am Acad Dermatol. 2024 Oct;91(4):619-648. doi: 10.1016/j.jaad.2023.10.072. Epub 2024 Jan 26.
The breadth of therapeutic options for the management of dermatologic skin conditions continues to expand rapidly as exemplified by biologics and small molecule drug development. While dermatologists and health care providers are aware of the underlying mechanisms and indications for these therapeutics, there is a recognized practice gap due to an incomplete understanding of the safety of these medications in women of childbearing age during the prepartum, antepartum, and postpartum phases. Although a two-part continuing medical education review was published regarding the prescribing practices and safety profiles of these new therapeutics in women of childbearing age while pregnant or lactating in 2014, many new medications have been approved since then. Herein, we will update the safety of dermatologic therapies during pregnancy and Part II will review the safety of medications during lactation.
随着生物制剂和小分子药物开发等领域的发展，皮肤科疾病治疗选择的范围迅速扩大。皮肤科医生和医疗保健提供者虽然了解这些治疗药物的潜在机制和适应证，但由于对育龄期妇女产前、产时和产后阶段这些药物安全性的认识不足，导致存在实践差距。虽然 2014 年发表了两部分继续教育审查，内容涉及这些新的治疗药物在育龄期妇女怀孕期间或哺乳期的处方实践和安全性概况，但此后又有许多新药获得批准。在此，我们将更新妊娠期皮肤科治疗药物的安全性，第二部分将审查哺乳期药物的安全性。
